Latest Headlines

Latest Headlines

BioDelivery snags new FDA approval for Onsolis after ditching Meda partnership

BioDelivery Sciences' Onsolis, a cancer pain treatment that makes use of the company's buccal delivery platform, picked up a new FDA approval for a reformulation of the treatment, which is expected to return to the U.S. market in 2016. BioDelivery earlier this year pulled out of a commercialization partnership with Sweden's Meda, which decided to focus more on respiration, and BioDelivery is currently looking for a new partner.

MonoSol targets drug film rival's revenue in updated court complaint

Warren, NJ-based MonoSol Rx aims to get compensated after rival BioDelivery Sciences International ($BDSI) received $60 million in revenue from drug-delivery tech that is included in a

Monosol Rx sues competitors over thin-film patent

Oral thin films are a potentially game-changing drug-delivery technology. So, unfortunately, it is only natural that as companies compete for position in this space lawyers would have to get

BDSI, Meda, FDA talk about streamlining REMS for Onsolis

Raleigh, NC-based BioDelivery Sciences International has disclosed a July meeting with the FDA and Swedish pharmaceutical company Meda regarding the Onsolis cancer-pain treatment. The talks centered